- Denali Therapeutics (NASDAQ:DNLI): Q1 GAAP EPS of -$0.41 misses by $0.02.
- Revenue of $4.2M (+556.3% Y/Y) beats by $1.22M.
- Press Release
- More news on: Denali Therapeutics Inc., Earnings news and commentary, Healthcare stocks news,
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 10:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
U.S. stocks were mixed, with the Dow Jones gaining around 70 points on Wednesday. Shares of Louisiana-Pacific Corporation (NYSE:LPX) rose sharply d...
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal sto...